In prostate cancer, miR-32-5p regulates the expression of BCL-2-interacting killer (BIK), a proapoptotic protein belonging to the BCL-2 family, and induces resistance to cisplatin-induced apoptosis [33]. This evidence concerns the gene BCL2 and prostate carcinoma.